Georgina Long, MD
At the 2017 ASCO Annual Meeting, investigators reported 5-year follow-up data from a phase II study of dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with BRAF
V600-mutant unresectable or metastatic melanoma.
OncLive: Could you provide an overview of this long-term follow-up?
For the dabrafenib and trametinib phase I/II study, we are now reporting the 5-year PFS and OS. Overall, 13% of patients are progression-free at 5 years, which is pretty significant. When we turn to the OS, we know that about 28% of patients are still alive at 5 years. If we look at the subgroup that have less than 3 metastatic sites and a normal LDH at best line, the figures are even better. We have an OS of 51%...so pretty significant—that is more than half of the patients with lower burden of disease and lower LDH alive at 5 years having been treated with dabrafenib/trametinib. These are actually the same subset of patients that do very well long term on immunotherapy, as well.
... to read the full story